Market overview
The global biomarker discovery market is worth USD 8.7 bn in 2026 and is forecast to reach USD 25.7 bn by 2036, growing at a 11.5% CAGR. United States is the largest country market and Genomics and sequencing is the largest by technology segment.
| Scope | Services, assays, platforms and instruments used to discover and validate biomarkers for drug development and diagnostics, covering genomic, proteomic, metabolomic and imaging-based approaches. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 7.8 bn |
| Value 2026 | USD 8.7 bn |
| Value 2036 | USD 25.7 bn |
| CAGR 2026-2036 | 11.5% |
| Volume 2026 | 104 thousand programmes |
| Volume 2036 | 266 thousand programmes |
| Average price 2026 | USD 83,340 per programme |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Biomarker Discovery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 8.7 bn |
| 2027 | USD 9.7 bn |
| 2028 | USD 10.8 bn |
| 2029 | USD 12.0 bn |
| 2030 | USD 13.4 bn |
| 2031 | USD 14.9 bn |
| 2032 | USD 16.6 bn |
| 2033 | USD 18.5 bn |
| 2034 | USD 20.7 bn |
| 2035 | USD 23.1 bn |
| 2036 | USD 25.7 bn |
Biomarker Discovery market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Proteomics | 30.0% | 32.1% | USD 2.6 bn | 12.2% |
| Genomics and sequencing | 34.0% | 33.3% | USD 2.9 bn | 11.2% |
| Metabolomics | 12.0% | 11.2% | USD 1.0 bn | 10.8% |
| Imaging and digital biomarkers | 14.0% | 15.6% | USD 1.2 bn | 12.8% |
| Other | 10.0% | 7.8% | USD 866 mn | 8.8% |
By end user
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmaceutical and biotechnology | 56.0% | 56.3% | USD 4.8 bn | 11.6% |
| Academic and research institutes | 22.0% | 18.4% | USD 1.9 bn | 9.6% |
| Contract research organisations | 22.0% | 25.3% | USD 1.9 bn | 13.1% |
By biomarker class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Genomic | 32.0% | 30.0% | USD 2.8 bn | 10.8% |
| Proteomic | 28.0% | 28.0% | USD 2.4 bn | 11.5% |
| Metabolomic | 14.0% | 15.0% | USD 1.2 bn | 12.3% |
| Transcriptomic | 16.0% | 16.0% | USD 1.4 bn | 11.5% |
| Epigenetic and others | 10.0% | 11.0% | USD 866 mn | 12.6% |
By disease area
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 48.0% | 47.0% | USD 4.2 bn | 11.3% |
| Neurology | 16.0% | 17.0% | USD 1.4 bn | 12.2% |
| Cardiovascular | 12.0% | 11.0% | USD 1.0 bn | 10.5% |
| Immunology | 14.0% | 14.0% | USD 1.2 bn | 11.5% |
| Other | 10.0% | 11.0% | USD 866 mn | 12.6% |
By offering
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Instruments | 30.0% | 26.0% | USD 2.6 bn | 9.9% |
| Consumables and reagents | 34.0% | 33.0% | USD 2.9 bn | 11.2% |
| Software and informatics | 14.0% | 17.0% | USD 1.2 bn | 13.7% |
| Contract services | 22.0% | 24.0% | USD 1.9 bn | 12.5% |
Top 25 countries for biomarker discovery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.5% of 2026 revenue and the 25 countries below together hold 96.8%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 3.6 bn | 42.0% | USD 10.2 bn | 10.8% |
| 2 | China | USD 1.0 bn | 12.0% | USD 4.1 bn | 14.8% |
| 3 | Germany | USD 606 mn | 7.0% | USD 1.6 bn | 10.3% |
| 4 | United Kingdom | USD 519 mn | 6.0% | USD 1.4 bn | 10.7% |
| 5 | Japan | USD 433 mn | 5.0% | USD 1.1 bn | 9.3% |
| 6 | France | USD 346 mn | 4.0% | USD 926 mn | 10.3% |
| 7 | Canada | USD 346 mn | 4.0% | USD 977 mn | 10.9% |
| 8 | South Korea | USD 303 mn | 3.5% | USD 977 mn | 12.4% |
| 9 | Switzerland | USD 260 mn | 3.0% | USD 694 mn | 10.3% |
| 10 | India | USD 260 mn | 3.0% | USD 977 mn | 14.2% |
| 11 | Netherlands | USD 89 mn | 1.0% | USD 270 mn | 11.7% |
| 12 | Spain | USD 84 mn | 1.0% | USD 255 mn | 11.7% |
| 13 | Italy | USD 68 mn | 0.8% | USD 206 mn | 11.8% |
| 14 | Australia | USD 64 mn | 0.7% | USD 193 mn | 11.7% |
| 15 | Sweden | USD 51 mn | 0.6% | USD 154 mn | 11.7% |
| 16 | Belgium | USD 48 mn | 0.6% | USD 147 mn | 11.7% |
| 17 | Singapore | USD 45 mn | 0.5% | USD 154 mn | 13.1% |
| 18 | Israel | USD 39 mn | 0.5% | USD 118 mn | 11.8% |
| 19 | Denmark | USD 29 mn | 0.3% | USD 90 mn | 11.8% |
| 20 | Taiwan | USD 28 mn | 0.3% | USD 95 mn | 13.1% |
| 21 | Brazil | USD 23 mn | 0.3% | USD 75 mn | 12.7% |
| 22 | Austria | USD 21 mn | 0.2% | USD 64 mn | 12.0% |
| 23 | Ireland | USD 16 mn | 0.2% | USD 51 mn | 12.1% |
| 24 | Norway | USD 16 mn | 0.2% | USD 49 mn | 12.1% |
| 25 | Poland | USD 15 mn | 0.2% | USD 51 mn | 13.3% |
| Rest of world | USD 274 mn | 3.2% | USD 779 mn | 11.0% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Thermo Fisher Scientific
- Illumina
- Agilent Technologies
- Charles River Laboratories
- Qiagen
- Danaher
- Revvity
Group 2: Regional and specialist players
- Evotec
- Bruker
- Standard BioTools
- Metabolon
- Quanterix
- Biognosys
- Eurofins
Group 3: Emerging and niche players
- Caprion
- Nautilus Biotechnology
- Seer
- Alamar Biosciences
- Owlstone Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the biomarker discovery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 11.5% is calculated from the resulting values.
The market is divided by technology, by end user, by biomarker class, by disease area, by offering. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the biomarker discovery market?
The global biomarker discovery market is estimated at USD 7.8 bn in 2025 and USD 8.7 bn in 2026.
How fast will the biomarker discovery market grow?
It is forecast to reach USD 25.7 bn by 2036, a compound annual growth rate of 11.5% from 2026, an increase of USD 17.1 bn.
Which country is the largest market for biomarker discovery?
United States is the largest market by revenue at USD 3.6 bn in 2026, 42.0% of the global total. The three largest countries together hold 61.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 14.8% a year from 2026 to 2036.
Which biomarker discovery segment is largest?
In the by technology split, Genomics and sequencing is the largest segment with 34.0% of 2026 revenue.
Who are the leading biomarker discovery companies?
Global leaders include Thermo Fisher Scientific, Illumina, Agilent Technologies, Charles River Laboratories.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Prefilled SyringeUSD 8.5 bn · 8.5% CAGR
- Pharmaceutical LabelingUSD 9.0 bn · 5.8% CAGR
- Healthcare Reimbursement OptimizationUSD 8.2 bn · 10.5% CAGR
- Protein PurificationUSD 9.3 bn · 9.0% CAGR
- Cell TherapyUSD 9.4 bn · 20.0% CAGR
- Pharmaceutical ClosureUSD 7.9 bn · 5.6% CAGR
- Digital TherapeuticsUSD 7.9 bn · 20.0% CAGR
- Softgel CapsuleUSD 9.6 bn · 6.6% CAGR